We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma.
- Authors
Liu, Qi; Zhu, Hongda; Liu, Yun; Musetti, Sara; Huang, Leaf
- Abstract
Approximately, 50% of human melanomas are driven by BRAF mutations, which produce tumors that are highly immunosuppressive and often resistant to vaccine therapy. We introduced lipid-coated calcium phosphate nanoparticles (LCP NPs) as a carrier to efficiently deliver a tumor-specific antigen, the BRAFV600E peptide, to drive dendritic cell (DC) maturation and antigen presentation in C57BL6 mice. The BRAF peptide vaccine elicited a robust, antigen-specific cytotoxic T cell response and potent tumor growth inhibition in a murine BRAF-mutant melanoma model. Advanced BRAF-specific immune response was illustrated by IFN-γ production assay and cytotoxic T lymphocyte (CTL) assay. Remodeling of immunosuppressive modules within the tumor microenvironment further facilitated CTL infiltration. Thus, using LCP NPs to deliver the BRAF peptide vaccine is a promising strategy for the BRAF-mutant melanoma therapy.
- Subjects
MELANOMA treatment; CANCER immunotherapy; PEPTIDES; BRAF genes; CYTOTOXIC T cells; TUMOR microenvironment; THERAPEUTICS
- Publication
Cancer Immunology, Immunotherapy, 2018, Vol 67, Issue 2, p299
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-017-2079-7